Wedbush Maintains Outperform on Spyre Therapeutics, Raises Price Target to $130
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and raises the price target from $100 to $130.
Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and raises the price target from $100 to $130.